General
Preferred name
TIPRANAVIR
Synonyms
PNU-140690 ()
Aptivus ()
U-140690 ()
PNU-140690E ()
Tipranavir sodium ()
TIPRANAVIR DISODIUM ()
Tipranavir-d4 ()
Tipranavir C-14 ()
P&D ID
PD013797
CAS
174484-41-4
1141509-98-9
191150-83-1
1217819-15-2
Tags
available
drug
drug candidate
Approved by
FDA
First approval
2005
Drug indication
Human immunodeficiency virus infection
HIV infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tipranavir is an anti-HIV-1 agent. It inhibits the viral protease. (GtoPdb)
DESCPRITION Tipranavir is an HIV-1 protease inhibitor that inhibits the virus-specific processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.
DESCRIPTION Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM[1][2]. Tipranavir inhibits SARS-CoV-2 3CLpro activity[3].
PRICE 643
DESCRIPTION Tipranavir is a protease inhibitor that inhibits HIV-1 resistant to more than 1 protease inhibitor .Tipranavir effectively inhibits HIV-1 protease enzyme activity and dimerisation and has potent activity against multiple protease inhibitor (PI) HIV-1 isolates (IC50 of 66-410 nM). Tipranavir inhibits SARS-CoV-2 3CLpro activity. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
8
Compound Sets
17
Cayman Chemical Bioactives
ChEMBL Approved Drugs
CZ-OPENSCREEN Bioactive Library
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
External IDs
112
Properties
(calculated by RDKit )
Molecular Weight
602.21
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
11
Ring Count
4
Aromatic Ring Count
3
cLogP
7.33
TPSA
105.59
Fraction CSP3
0.35
Chiral centers
2.0
Largest ring
6.0
QED
0.22
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
HIV-1 protease
SARS CoV-1 3CLpro
HIV
HIV Protease
SARS-CoV
Therapeutic Class
Anti-HIV Agents
Pathway
Anti-infection
Metabolic Enzyme/Protease
Microbiology/virology
Proteases/Proteasome
Source data